Julian Peiser-Oliver

Julian Peiser-Oliver

Auto-generated profile, based on publicly available information

Julian Peiser-Oliver


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2025 in bioRxiv
Verified
Preprint
Open access
RCRyan P. Cantwell Chater
Ryan P. Cantwell Chater
JPJulian Peiser-Oliver
Julian Peiser-Oliver
TPTanmay K. Pati
Tanmay K. Pati
AQAda S. Quinn
Ada S. Quinn
ILIrina Lotsaris
Irina Lotsaris
ASAzadeh Shahsavar
Azadeh Shahsavar
Chronic neuropathic pain, caused by nerve damage or disease, is increasing in prevalence, but current treatments are ineffective and over-reliant on opioids. The neuronal glycine transporter, GlyT2, regulates inhibitory glycinergic neurotransmission and represents a promising target for new analgesics. However, most GlyT2 inhibitors cause significant side effects, in part due to irreversible inhibition at analgesic doses. Here we develop a reversible inhibitor of GlyT2, RPI-GLYT2-82, and identify its binding site by determining cryo-EM structures of human GlyT2. We capture three fundamental conformational states of GlyT2 in the substrate-free state, and bound to either glycine, RPI-GLYT2-82 or the pseudo-irreversible inhibitor ORG25543. We demonstrate that RPI-GLYT2-82 dissociates from GlyT2 faster than ORG25543, providing analgesia in mouse neuropathic pain models without on-target side-effects or addiction liability. Our data provide a mechanistic understanding of allosteric inhibition of glycine transport, enabling structure-based design of non-opioid analgesics.